Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study

被引：0
|
作者：
Bahce, I. [1 ]
Schneiders, F. L. [2 ]
Hashemi, S. [1 ]
Veltman, J. [3 ]
Daniels, H. [4 ]
Fransen, M. [4 ]
Radonic, T. [5 ]
Ulas, E. [6 ]
Houda, I.
Barlo, N. [7 ]
Disselhorst, M. [8 ]
van Laren, M. [9 ]
Tiemessen, M. [9 ]
Tarasevych, S. [10 ]
van Haarst, J. M. M. [11 ]
van Tilburg, P. [12 ]
Kunst, P. [13 ]
Moons-Pasic, A. [14 ]
de Gruijl, T. D. [15 ]
Senan, S. [2 ]
机构：
[1] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Pulmonary Dis Dept, Amsterdam, Netherlands
[2] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Radiat Oncol Dept, Amsterdam, Netherlands
[3] Vrije Univ Med Ctr VUmc, Pulmonary Med, Amsterdam UMC, Amsterdam, Netherlands
[4] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Pulmonol Dept, Amsterdam, Netherlands
[5] Vrije Univ Med Ctr VUmc, Pathol, Amsterdam UMC, Amsterdam, Netherlands
[6] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Pulmonol Dept, Amsterdam, Netherlands
[7] Noordwest Ziekenhuisgroep, Pulmonol, Alkmaar, Netherlands
[8] Noordwest Ziekenhuisgroep Alkmaar, Pulmonol Dept, Alkmaar, Netherlands
[9] Dijklander Hosp, Pulmonary Dis Dept, Hoorn, Netherlands
[10] Zaans Med Ctr, Pulmonary Dis Dept, Zaandam, Netherlands
[11] Tergooi Ziekenhuizen, Pulmonol Dept, Hilversum, Netherlands
[12] Tergooi Hosp Iocatie Hilversum, Pulmonary Dis Dept, Hilversum, Netherlands
[13] OLVG Hosp, Pulmonary Dis Dept, Amsterdam, Netherlands
[14] OLVG locat West, Pulmonary Dis Dept, Amsterdam, Netherlands
[15] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Med Oncol Dept, Room CCA2 44, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1020P
引用
收藏
页码：S1021 / S1021
页数：1
相关论文
共 50 条
  • [41] Resistance patterns to anti-PD-1 therapy in metastatic melanoma
    Ozgun, Alpaslan
    Sondak, Vernon K.
    Markowitz, Joseph
    CHINESE CLINICAL ONCOLOGY, 2016, 5 (06)
  • [42] Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
    Das, Rituparna
    Verma, Rakesh
    Sznol, Mario
    Boddupalli, Chadra Sekhar
    Gettinger, Scott
    Kluger, Harriet
    Dhodapkar, Madhav
    Dhodapkar, Kavita
    CANCER RESEARCH, 2015, 75
  • [43] Anti-PD-1 Therapy in Melanoma
    Moreno, Blanca Hornet
    Parisi, Giulia
    Robert, Lidia
    Ribas, Anton
    SEMINARS IN ONCOLOGY, 2015, 42 (03) : 466 - 473
  • [44] Anti-PD-1 therapy in the frontline
    David Killock
    Nature Reviews Clinical Oncology, 2016, 13 (12) : 715 - 715
  • [45] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Gauci, Marie-Lea
    Boudou, Philippe
    Baroudjian, Barouyr
    Vidal-Trecan, Tiphaine
    Da Meda, Laetitia
    Madelaine-Chambrin, Isabelle
    Basset-Seguin, Nicole
    Bagot, Martine
    Pages, Cecile
    Mourah, Samia
    Resche-Rigon, Matthieu
    Pinel, Sylvine
    Sassier, Marion
    Rouby, Franck
    Eftekhari, Pirayeh
    Lebbe, Celeste
    Gautier, Jean-Francois
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
  • [46] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [47] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Marie-Léa Gauci
    Philippe Boudou
    Barouyr Baroudjian
    Tiphaine Vidal-Trecan
    Laetitia Da Meda
    Isabelle Madelaine-Chambrin
    Nicole Basset-Seguin
    Martine Bagot
    Cécile Pages
    Samia Mourah
    Matthieu Resche-Rigon
    Sylvine Pinel
    Marion Sassier
    Franck Rouby
    Pirayeh Eftekhari
    Céleste Lebbé
    Jean-François Gautier
    Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
  • [48] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
    Prithviraj, Prashanth
    McArthur, Grant A.
    Atkinson, Victoria
    Parente, Phillip
    Andrews, Miles Cameron
    Parakh, Sagun
    Cebon, Jonathan S.
    Klein, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
  • [50] The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma
    Zhou, Yu
    Ma, Baozhen
    Gao, Quanli
    Zhao, Lingdi
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (05) : 2238 - 2250
12345